Skip to main content
SpringerLink
Log in

Blood assessment of the expression levels of matrix metalloproteinase 9 (MMP9) and its natural inhibitor, TIMP1 genes in Iranian schizophrenic patients

  • Original Article
  • Published:
Metabolic Brain Disease Aims and scope Submit manuscript

Abstract

Schizophrenia (SCZ) is the most severe chronic mental disorder characterized by abnormal social behavior and disrupted emotions and thought. Like other complex neuropsychological disease, SCZ is caused by a combination of genetic and environmental factors but with a high concordance rate. So far, different genetic factors are revealed to be associated with increased risk of developing SCZ. One of the best ways to investigate the genetic basis of the complex disease is to discover the genetic underlying mechanisms of the defective clinical aspects of the patients. In this regard, genes involved in the developmental mechanisms of the brain such as long-term potentiation (LTP) process that is the basis of synaptic plasticity, memory and learning are considered as strong candidates for SCZ. The aim of the present study was to evaluate the expression levels of two genes that are involved in the LTP regulation in the developing and adult brain, Matrix metallopeptidase9 (MMP9) and TIMP metallopeptidase inhibitor 1 (TIMP1) genes in a blood assessment of schizophrenic patients in comparison to healthy controls by means of quantitative real time PCR. The results of the study showed a significant difference in MMP9/TIPM1 ratio between SCZ patients and healthy controls (P = 0.01). However, no significant difference was detected in the expression level of individual MMP9 and TIMP1 genes in SCZ patients versus healthy controls either in total numbers of subject or in sex based subgroups. Considering the relatively small sample size of the current study, there is a need to replicate this study with further investigations about the mechanism of association of these genes and their functions in the pathogenesis of the SCZ.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Andreasen NC (1982) Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry 39:784–788

    Article  CAS  PubMed  Google Scholar 

  • Association, AP (2013) Diagnostic and statistical manual of mental disorders (DSM-5®). Pub, American Psychiatric

    Book  Google Scholar 

  • Bhugra D (2005) The global prevalence of schizophrenia. PLoS Med 2:e151

    Article  PubMed  PubMed Central  Google Scholar 

  • Chen YC, Wu YR, Mesri M, Chen CM (2016) Associations of matrix metalloproteinase-9 and tissue inhibitory factor-1 polymorphisms with Parkinson disease in Taiwan. Medicine 95:e2672

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Domenici E, Wille DR, Tozzi F, Prokopenko I, Miller S, Mckeown A, Brittain C, Rujescu D, Giegling I, Turck CW (2010) Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One 5:e9166

    Article  PubMed  PubMed Central  Google Scholar 

  • Gardner J, Ghorpade A (2003) Tissue inhibitor of metalloproteinase (TIMP)-1: the TIMPed balance of matrix metalloproteinases in the central nervous system. J Neurosci Res 74:801–806

    Article  CAS  PubMed  Google Scholar 

  • Hamedani SY, Taheri M, Omrani MD, Sajjadi E, Mazdeh M, Panah AST, Sayad A (2016) Up regulation of MMP9 gene expression in female patients with multiple sclerosis. Human Antibodies:1–6

  • Hu W, Macdonald ML, Elswick DE, Sweet RA (2015) The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies. Ann N Y Acad Sci 1338:38–57

    Article  CAS  PubMed  Google Scholar 

  • Huntley GW (2012) Synaptic circuit remodelling by matrix metalloproteinases in health and disease. Nat Rev Neurosci 13:743–757

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kim Y, Zerwas S, Trace SE, Sullivan PF (2011) Schizophrenia genetics: where next? Schizophr Bull 37:456–463

    Article  PubMed  PubMed Central  Google Scholar 

  • Kim Y, Remacle AG, Chernov AV, Liu H, Shubayev I, Lai C, Dolkas J, Shiryaev SA, Golubkov VS, Mizisin AP (2012) The MMP-9/TIMP-1 axis controls the status of differentiation and function of myelin-forming Schwann cells in nerve regeneration. PLoS One 7:e33664

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lee JY, Kim HS, Choi HY, Oh TH, Yune TY (2012) Fluoxetine inhibits matrix metalloprotease activation and prevents disruption of blood–spinal cord barrier after spinal cord injury. Brain. doi:10.1093/brain/aws171

  • Lepeta K, Kaczmarek L (2015) Matrix metalloproteinase-9 as a novel player in synaptic plasticity and schizophrenia. Schizophr Bull. doi:10.1093/schbul/sbv036

  • LIN C-H, LANE H-Y, TSAI GE (2012) Glutamate signaling in the pathophysiology and therapy of schizophrenia. Pharmacol Biochem Behav 100:665–677

    Article  CAS  PubMed  Google Scholar 

  • Lorenzl S, Albers DS, Narr S, Chirichigno J, Beal MF (2002) Expression of MMP-2, MMP-9, and MMP-1 and their endogenous counterregulators TIMP-1 and TIMP-2 in postmortem brain tissue of Parkinson's disease. Exp Neurol 178:13–20

    Article  CAS  PubMed  Google Scholar 

  • Lorenzl S, Albers DS, Relkin N, Ngyuen T, Hilgenberg SL, Chirichigno J, Cudkowicz ME, Beal MF (2003) Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer’s disease. Neurochem Int 43:191–196

    Article  CAS  PubMed  Google Scholar 

  • Michaluk P, Kaczmarek L (2007) Matrix metalloproteinase-9 in glutamate-dependent adult brain function and dysfunction. Cell Death Differ 14:1255–1258

    Article  CAS  PubMed  Google Scholar 

  • Mroczko B, Koper OM, Groblewska M, Zboch M, Kulczynska-Przybik A, Szmitkowski M, Kornhuber J, Lewczuk P (2014) Matrix metalloproteinase-9 (Mmp-9) and its tissue inhibitor-1 (Timp-1) as biomarkers of Alzheimer's disease. Alzheimer's & Dementia: J Alzheimer's Assoc 10:520

    Article  Google Scholar 

  • Nagase H, Visse R, Murphy G (2006) Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 69:562–573

    Article  CAS  PubMed  Google Scholar 

  • Nagy V, Bozdagi O, Matynia A, Balcerzyk M, Okulski P, Dzwonek J, Costa RM, Silva AJ, Kaczmarek L, Huntley GW (2006) Matrix metalloproteinase-9 is required for hippocampal late-phase long-term potentiation and memory. J Neurosci 26:1923–1934

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nazdik MK, Taheri M, Omrani MD, Sajjadi E, Arsang-Jang S, Koohpar ZK., Inoko H, Sayad A. (2016). Increased expression ratio of matrix metalloproteinase-9 (MMP9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) RNA levels in Iranian multiple sclerosis patients. Human Antibodies , 1-5

  • Niitsu T, Ishima T, Yoshida T, Hashimoto T, Matsuzawa D, Shirayama Y, Nakazato M, Shimizu E, Hashimoto K, Iyo M (2014) A positive correlation between serum levels of mature brain-derived neurotrophic factor and negative symptoms in schizophrenia. Psychiatry Res 215:268–273

    Article  CAS  PubMed  Google Scholar 

  • Noroozi R, Taheri M, Movafagh A, Mirfakhraie R, Solgi G, Sayad A, Mazdeh M, Darvish H (2016) Glutamate receptor, metabotropic 7 (GRM7) gene variations and susceptibility to autism: a case–control study. Autism Res 9:1161–1168

    Article  PubMed  Google Scholar 

  • Okulski P, Jay TM, Jaworski J, Duniec K, Dzwonek J, Konopacki FA, Wilczynski GM, Sánchez-Capelo A, Mallet J, Kaczmarek L (2007) TIMP-1 abolishes MMP-9-dependent long-lasting long-term potentiation in the prefrontal cortex. Biol Psychiatry 62:359–362

    Article  CAS  PubMed  Google Scholar 

  • Rivera S, Khrestchatisky M, Kaczmarek L, Rosenberg GA, Jaworski DM (2010) Metzincin proteases and their inhibitors: foes or friends in nervous system physiology? J Neurosci 30:15337–15357

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ruzzo EK, Geschwind DH (2016) Schizophrenia genetics complements its mechanistic understanding. Nat Neurosci 19:523–525

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shibasaki C, Takebayashi M, Itagaki K, Abe H, Kajitani N, Okada-Tsuchioka M, Yamawaki S (2016) Altered serum levels of matrix metalloproteinase-2,-9 in response to electroconvulsive therapy for mood disorders. Int J Neuropsychopharmacol. doi:10.1093/ijnp/pyw019

  • Soler RC, Gui YH, Linask KK, Muschel RJ (1995) MMP-9 (gelatinase B) mRNA is expressed during mouse neurogenesis and may be associated with vascularization. Dev Brain Res 88:37–52

    Article  Google Scholar 

  • Szklarczyk A, Lapinska J, Rylski M, Mckay RD, Kaczmarek L (2002) Matrix metalloproteinase-9 undergoes expression and activation during dendritic remodeling in adult hippocampus. J Neurosci 22:920–930

    CAS  PubMed  Google Scholar 

  • Tandon R, Gaebel W, Barch DM, Bustillo J, Gur RE, Heckers S, Malaspina D, Owen MJ, Schultz S, Tsuang M (2013) Definition and description of schizophrenia in the DSM-5. Schizophr Res 150:3–10

    Article  PubMed  Google Scholar 

  • Vaillant C, Meissirel C, Mutin M, Belin M-F, Lund LR, Thomasset N (2003) MMP-9 deficiency affects axonal outgrowth, migration, and apoptosis in the developing cerebellum. Mol Cell Neurosci 24:395–408

    Article  CAS  PubMed  Google Scholar 

  • Van Den Steen PE, Dubois B, Nelissen I, Rudd PM, Dwek RA, Opdenakker G (2002) Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 37:375–536

    Article  PubMed  Google Scholar 

  • Wilczynski GM, Konopacki FA, Wilczek E, Lasiecka Z, Gorlewicz A, Michaluk P, Wawrzyniak M, Malinowska M, Okulski P, Kolodziej LR (2008) Important role of matrix metalloproteinase 9 in epileptogenesis. J Cell Biol 180:1021–1035

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yamamori H, Hashimoto R, Ishima T, Kishi F, Yasuda Y, Ohi K, Fujimoto M, Umeda-Yano S, Ito A, Hashimoto K (2013) Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with clozapine. Neurosci Lett 556:37–41

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biology, Central Tehran Branch, Islamic Azad University, Tehran, Iran

    Shahrzad Rahimi & Elham Moslemi

  2. Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, PO Box 1985717443, Tehran, Iran

    Arezou Sayad, Soudeh Ghafouri-Fard & Mohammad Taheri

  3. Urogenital Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    Mohammad Taheri

Authors
  1. Shahrzad Rahimi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arezou Sayad
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elham Moslemi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Soudeh Ghafouri-Fard
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mohammad Taheri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Arezou Sayad or Mohammad Taheri.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rahimi, S., Sayad, A., Moslemi, E. et al. Blood assessment of the expression levels of matrix metalloproteinase 9 (MMP9) and its natural inhibitor, TIMP1 genes in Iranian schizophrenic patients. Metab Brain Dis 32, 1537–1542 (2017). https://doi.org/10.1007/s11011-017-0043-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11011-017-0043-z

Keywords

Search

Navigation